NASDAQ:CALA Calithera Biosciences (CALA) Stock Price, News & Analysis → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Free CALA Stock Alerts $0.04 -0.01 (-20.00%) (As of 04/17/2024 ET) Add Compare Share Share Today's Range$0.02▼$0.0450-Day Range$0.02▼$0.0552-Week Range$0.01▼$0.50Volume5,257 shsAverage Volume1,618 shsMarket Capitalization$194,800.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsSocial MediaSustainabilityStock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsSocial MediaSustainability Get Calithera Biosciences alerts: Email Address Ad Gold Safe ExchangeThe “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.Click here now to download the free Precious Metals Buying Guide! About Calithera Biosciences Stock (NASDAQ:CALA)Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Read More CALA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CALA Stock News HeadlinesApril 14, 2024 | americanbankingnews.comCalithera Biosciences (NASDAQ:CALA) Coverage Initiated by Analysts at StockNews.comFebruary 24, 2024 | uk.investing.comArcus Biosciences Inc (RCUS)April 18, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.August 12, 2023 | npr.orgChristina CalaJune 29, 2023 | seekingalpha.comCalithera Biosciences cancels special meeting due to lack of quorumJune 1, 2023 | finance.yahoo.comCALA - Calithera Biosciences, Inc.May 20, 2023 | finanznachrichten.deCalithera Biosciences, Inc.: Calithera Biosciences Announces Update on Complete Liquidation and DissolutionMay 19, 2023 | travel.usnews.comCala MarioluApril 18, 2024 | Gold Safe Exchange (Ad)The “Perfect Storm” for GoldGold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.May 19, 2023 | seekingalpha.comCalithera Biosciences plans special meeting to seek approval for liquidation and dissolution planMay 19, 2023 | finance.yahoo.comCalithera Biosciences Announces Update on Complete Liquidation and DissolutionMay 13, 2023 | travel.usnews.comCala LlombardsMay 12, 2023 | investing.comCalithera Biosciences Inc (CALA) Earnings Dates & ReportsJanuary 11, 2023 | marketwatch.comCalithera Biosciences Shares Plummet on Liquidation Plans >CALAJanuary 11, 2023 | marketwatch.comCalithera Biosciences to Liquidate >CALAJanuary 10, 2023 | finance.yahoo.comBiotech company Calithera plans its own death. Will others follow?January 9, 2023 | finanznachrichten.deCalithera Biosciences, Inc.: Calithera Biosciences Announces Board Approval of Complete Liquidation and DissolutionJanuary 9, 2023 | markets.businessinsider.comCalithera Biosciences Board Of Directors Determine Dissolution Of CompanyJanuary 9, 2023 | finance.yahoo.comCalithera Biosciences Stock Nosedives On Complete Liquidation, DissolutionJanuary 9, 2023 | finance.yahoo.comCalithera Biosciences Announces Board Approval of Complete Liquidation and DissolutionNovember 15, 2022 | finanznachrichten.deCalithera Biosciences, Inc.: Calithera Biosciences Reports Third Quarter 2022 Financial Results and Business UpdateNovember 15, 2022 | seekingalpha.comCalithera Biosciences, Inc. (CALA) Q3 2022 Earnings Call TranscriptNovember 15, 2022 | finance.yahoo.comCalithera Biosciences Reports Third Quarter 2022 Financial Results and Business UpdateNovember 8, 2022 | finance.yahoo.comCalithera Biosciences to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022October 3, 2022 | marketwatch.comCalithera Biosciences Gets FDA Fast Track For Lung Cancer DrugOctober 3, 2022 | nasdaq.comCalithera Gets FDA Fast Track Designation For Sapanisertib For Squamous Lung Cancer TreatmentOctober 3, 2022 | finance.yahoo.comCalithera's stock is up 14% after announcing Fast Track designation for lung-cancer drug candidateSee More Headlines Receive CALA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Calithera Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today4/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CALA CUSIPN/A CIK1496671 Webwww.calithera.com Phone(650) 870-1000FaxN/AEmployees8Year Founded2010Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$9.75 million Price / Sales0.02 Cash FlowN/A Price / Cash FlowN/A Book Value($0.40) per share Price / Book-0.10Miscellaneous Outstanding Shares4,870,000Free Float4,550,000Market Cap$194,800.00 OptionableNot Optionable Beta-0.17 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Susan M. Molineaux Ph.D. (Age 70)Founder, CEO, President & Director Comp: $625.81kMs. Stephanie Wong (Age 50)CFO & Secretary Comp: $752.42kDr. Christopher J. Molineaux Ph.D. (Age 71)Senior Vice President of Development Comp: $405kMr. Frank Parlati Ph.D. (Age 55)Senior Vice President of Research Key CompetitorsAthersysNASDAQ:ATHXAptevo TherapeuticsNASDAQ:APVOAmpio PharmaceuticalsNYSE:AMPEScopus BioPharmaNASDAQ:SCPSAllarity TherapeuticsNASDAQ:ALLRView All Competitors CALA Stock Analysis - Frequently Asked Questions How have CALA shares performed in 2024? Calithera Biosciences' stock was trading at $0.03 at the beginning of 2024. Since then, CALA shares have increased by 33.3% and is now trading at $0.04. View the best growth stocks for 2024 here. How were Calithera Biosciences' earnings last quarter? Calithera Biosciences, Inc. (NASDAQ:CALA) issued its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($3.00) EPS for the quarter, beating the consensus estimate of ($4.60) by $1.60. The biotechnology company earned $6.75 million during the quarter. During the same period in the previous year, the company posted ($6.40) EPS. When did Calithera Biosciences' stock split? Calithera Biosciences shares reverse split on Wednesday, June 15th 2022. The 1-20 reverse split was announced on Wednesday, June 15th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 15th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Calithera Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Calithera Biosciences investors own include Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), Celadon Group (CGI), Dynavax Technologies (DVAX), Rigel Pharmaceuticals (RIGL), First Solar (FSLR), Plug Power (PLUG) and Sorrento Therapeutics (SRNE). How do I buy shares of Calithera Biosciences? Shares of CALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CALA) was last updated on 4/18/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsThe “Perfect Storm” for GoldGold Safe ExchangeUrgent alert: open this for a huge profit potentialTimothy SykesTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsBiden out June 13; Kamala won’t replace him?Paradigm PressThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calithera Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.